Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Efficacy and Safety of BIA 9-1067 in Idiopathic Parkinson's Disease Patients With "Wearing-off" Phenomenon Treated With Levodopa Plus a Dopa Decarboxylase Inhibitor (DDCI): a Double-blind, Randomised, Placebo-controlled, Parallel-group, Multicentre Clinical Study

Next Previous
Trial Profile

Efficacy and Safety of BIA 9-1067 in Idiopathic Parkinson's Disease Patients With "Wearing-off" Phenomenon Treated With Levodopa Plus a Dopa Decarboxylase Inhibitor (DDCI): a Double-blind, Randomised, Placebo-controlled, Parallel-group, Multicentre Clinical Study

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 13 Jun 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Opicapone (Primary) ; Benserazide; Carbidopa; Levodopa
  • Indications Parkinson's disease
  • Focus Registrational; Therapeutic Use
  • Acronyms BIPARK-II
  • Sponsors Bial; BIAL - Portela C S.A.

    • Most Recent Events

    • 06 Jun 2022 According to a Neurocrine Biosciences media release, Results of post-hoc analysis of ( NCT01568073 and NCT01227655) are being shared at SLEEP 2022, the annual meeting of the Associated Professional Sleep Societies, LLC (APSS) being held June 4-8 in Charlotte, North Carolina. The oral presentation of these data will take place on June 8
    • 06 Jun 2022 Results of post-hoc analysis of ( NCT01568073 and NCT01227655) published in the Neurocrine Biosciences Media Release
    • 16 Oct 2021 According to a Neurocrine Biosciences media release, pooled analysis data from BIPARK-I and BIPARK-II will be presented at the American Neurological Association 2021 Virtual Annual Meeting
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top